<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690883</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10425</org_study_id>
    <nct_id>NCT02690883</nct_id>
  </id_info>
  <brief_title>Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy</brief_title>
  <official_title>Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, parallel study to evaluate effect of exenatide on
      24h-UAER in patients with diabetic nephropathy.

      Screening will be made to select eligible participants before intervention. The trial will
      include 2-week run-in period of stable doses of glargine plus lispro insulin and 24-week
      treatment period. After the run-in period, patients were randomly assigned to one of two
      groups for antihyperglycaemic therapies for a total of 24-weeks: glargine plus exenatide and
      continued glargine plus lispro insulin. The treatment of exenatide will be initiated by 5ug
      bid, and uptitrated to 10 ug bid after 4 weeks and then maintained at 10ug bid until the
      completion of the study. Lispro insulin will be initially treated according to the insulin
      dosage of previous antihyperglycaemic therapies, and further titrated up at 4-week intervals
      until to reach the target fasting blood glucose (FPG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

      To evaluate effect of exenatide on 24-UAER in patients with diabetic nephropathy

      Hypothesis:

      Compared with glargine plus lispro group, at 24 weeks, glargine plus exenatide group can: 1)
      take more significant reduction of 24h-UAER; 2) take more reduction of ACR; 3) take more
      weight loss, blood pressure reduction; 4) take lower hypoglycemia incidence and less insulin
      dosage.

      Primary endpoint： The proportion of reduction of 24h-UAER(urinary albumin excretion rates)

      Secondary endpoints： 24h-UAER at 24 weeks; the rate of urinary albumin to creatinine
      ratio(ACR) change at 24 weeks; HbA1c, FPG,PPG, weight , BP

      Treatment duration： 24weeks

      Patient/Sites： 90 patients / 3 sites

      Timeline (best case)： Planed duration of recruitment period: 6 month Planed date for first
      screening: 1 October 2015 Planed completion of the last subject: 1 March 2017 Planned
      completion of clinical trial report: 30 October 2017
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage change of 24h-UAER(urinary albumin excretion rates) from baseline at Week 24</measure>
    <time_frame>from baseline at Week 24</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Lispro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG &lt;7.2mmol/L and &gt;4.4mmol/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG &lt;7.2mmol/L and &gt;4.4mmol/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lispro</intervention_name>
    <description>Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG &lt;10.0mmol/L.</description>
    <arm_group_label>Lispro</arm_group_label>
    <other_name>Humalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures.

          2. Diagnosed with type 2 diabetes with HbA1c ≥ 7.0% and ≤ 10.0% at screening (the result
             is valid for seven days).

          3. Men and women (non-pregnant and using a medically approved birth-control method) aged
             from 18 to 70 at screening.

          4. Body mass index (BMI) ≥18 and ≤35 kg/m2.

          5. Blood Pressure (BP) ≥ 90/60mmHg and ≤160/100mmHg.

        6.24h urinary albumin excretion rate (UAE) &gt;0.3g/24h after 3 months treatment with several
        hypoglycemic agents (sulphonylureas, metformin, AG-inhibitor, meglitinides or insulin),
        ACEI/ARB and salt restriction(the result is valid for seven days).

        7.GFR &gt;45ml/min(the result is valid for seven days).

        Exclusion Criteria:

        1．Women who are pregnant, intending to become pregnant during the study period, currently
        lactating females, or women of child-bearing potential not using highly effective,
        medically approved birth control methods.

        2. Diagnosis or history of:

          1. Type 1 diabetes mellitus, diabetes resulting from pancreatic injury or secondary forms
             of diabetes, eg, acromegaly or Cushing's syndrome.

          2. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma
             within the past 6 months.

             3. Previous treatment with any Thiazolidinediones (TZDs), dipeptidyl peptidase-4
             (DPP4) inhibitor or GLP-1 receptor agonists within the past one year.

             4. History of hypersensitivity reaction (e.g., anaphylaxis, angioedema, exfoliative
             skin conditions) to exenatide.

             5. Blood amylase and/or lipase &gt; 2 times the upper limit of the normal (ULN)
             laboratory range.

             6. Hyperkalemia (K+&gt;5.5mmol/L).

             7. eGFR ＜45ml/min/1.73m2.

             8. Patients without diabetic retinopathy.

             9. Triglycerides (fasting) &gt; 4.5 mmol/L (400 mg/dL) at screening or within 4 weeks
             prior to screening (by local laboratory).

             10. Patients with clinically apparent liver disease characterized by ALT or AST &gt; 3ULN
             confirmed on two consecutive measurements (by local laboratory) within 4 weeks prior
             to screening period.

             11. Significant cardiovascular history within the past 3 months prior to screening
             defined as: myocardial infarction, coronary angioplasty or bypass graft(s), valvular
             disease or repair, unstable angina pectoris, transient ischemic attack, or
             cerebrovascular accident.

             12. Congestive heart failure defined as New York Heart Association (NYHA) class III or
             IV.

             13. History of chronic pancreatitis or idiopathic acute pancreatitis.

             14. History of medullary thyroid carcinoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xue, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology &amp; Metabolism, Nanfang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhang, PhD</last_name>
    <phone>020-61641637</phone>
    <email>chenyuezhang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xu, PhD</last_name>
    <phone>020-61641637</phone>
    <email>xuww1988@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154.</citation>
    <PMID>17276798</PMID>
  </reference>
  <reference>
    <citation>Lim AKh. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis. 2014 Oct 15;7:361-81. doi: 10.2147/IJNRD.S40172. eCollection 2014. Review.</citation>
    <PMID>25342915</PMID>
  </reference>
  <reference>
    <citation>de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006 Aug;17(8):2100-5. Epub 2006 Jul 6.</citation>
    <PMID>16825327</PMID>
  </reference>
  <reference>
    <citation>Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes. 2013 Oct 15;4(5):190-201. doi: 10.4239/wjd.v4.i5.190. Review.</citation>
    <PMID>24147203</PMID>
  </reference>
  <reference>
    <citation>Lu B, Song X, Dong X, Yang Y, Zhang Z, Wen J, Li Y, Zhou L, Zhao N, Zhu X, Hu R. High prevalence of chronic kidney disease in population-based patients diagnosed with type 2 diabetes in downtown Shanghai. J Diabetes Complications. 2008 Mar-Apr;22(2):96-103. doi: 10.1016/j.jdiacomp.2007.08.001.</citation>
    <PMID>18280439</PMID>
  </reference>
  <reference>
    <citation>Lai X, Zhang AH, Chen SY, He L, Su CY, Fan MH, Wang T. Outcomes of stage 1-5 chronic kidney disease in Mainland China. Ren Fail. 2014 May;36(4):520-5. doi: 10.3109/0886022X.2013.875859. Epub 2014 Jan 23.</citation>
    <PMID>24456114</PMID>
  </reference>
  <reference>
    <citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.</citation>
    <PMID>8366922</PMID>
  </reference>
  <reference>
    <citation>Tomino Y. Pathogenesis and treatment of chronic kidney disease: a review of our recent basic and clinical data. Kidney Blood Press Res. 2014;39(5):450-89. doi: 10.1159/000368458. Epub 2014 Nov 30. Review.</citation>
    <PMID>25501571</PMID>
  </reference>
  <reference>
    <citation>Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19(17):3033-42. Review.</citation>
    <PMID>23176216</PMID>
  </reference>
  <reference>
    <citation>Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol. 2007 Apr;18(4):1227-38. Epub 2007 Mar 14.</citation>
    <PMID>17360951</PMID>
  </reference>
  <reference>
    <citation>Xu WW, Guan MP, Zheng ZJ, Gao F, Zeng YM, Qin Y, Xue YM. Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway. Cell Physiol Biochem. 2014;33(2):423-32. doi: 10.1159/000358623. Epub 2014 Feb 11.</citation>
    <PMID>24556697</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res. 2012;35(6):483-8. doi: 10.1159/000337929. Epub 2012 Jun 8.</citation>
    <PMID>22687869</PMID>
  </reference>
  <reference>
    <citation>Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med. 2013 Sep;231(1):57-61.</citation>
    <PMID>24064677</PMID>
  </reference>
  <reference>
    <citation>Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med. 2008 May 1;358(18):1970-1; discussion 1971-2.</citation>
    <PMID>18456920</PMID>
  </reference>
  <reference>
    <citation>Bloomgren G, Braum D, Kolterman O. Exenatide and rare adverse events. N Engl J med 2008; 358: 1971-2.</citation>
  </reference>
  <reference>
    <citation>Yanagisawa K, Ashihara J, Obara S, Wada N, Takeuchi M, Nishino Y, Maeda S, Ishibashi Y, Yamagishi S. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients. Diabetes Metab Res Rev. 2014 Nov;30(8):693-700. doi: 10.1002/dmrr.2537.</citation>
    <PMID>24639403</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Yaoming Xue</investigator_full_name>
    <investigator_title>Department of Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

